Zhuang Y, Liu K, He Q, Gu X, Jiang C, Wu J
MedComm (2020). 2023; 4(1):e203.
PMID: 36703877
PMC: 9870816.
DOI: 10.1002/mco2.203.
Huai Y, Hossen M, Wilhelm S, Bhattacharya R, Mukherjee P
Bioconjug Chem. 2019; 30(9):2247-2263.
PMID: 31408324
PMC: 6892461.
DOI: 10.1021/acs.bioconjchem.9b00448.
Li J, Shang W, Li Y, Fu S, Tian J, Lu L
Int J Nanomedicine. 2018; 13:5925-5936.
PMID: 30319257
PMC: 6171520.
DOI: 10.2147/IJN.S173914.
Wang J, Liu L, You Q, Song Y, Sun Q, Wang Y
Theranostics. 2018; 8(4):955-971.
PMID: 29463993
PMC: 5817104.
DOI: 10.7150/thno.22325.
Zhou Z, Song J, Nie L, Chen X
Chem Soc Rev. 2016; 45(23):6597-6626.
PMID: 27722328
PMC: 5118097.
DOI: 10.1039/c6cs00271d.
Liposome encapsulated perfluorohexane enhances radiotherapy in mice without additional oxygen supply.
Xu L, Qiu X, Zhang Y, Cao K, Zhao X, Wu J
J Transl Med. 2016; 14:268.
PMID: 27646172
PMC: 5028944.
DOI: 10.1186/s12967-016-1033-3.
Tumour pO2 can be increased markedly by mild hyperthermia.
Iwata K, Shakil A, Hur W, Makepeace C, Griffin R, Song C
Br J Cancer Suppl. 1996; 27:S217-21.
PMID: 8763884
PMC: 2150045.
Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.
Teicher B, Holden S, Dupuis N, Kakeji Y, Ikebe M, Emi Y
Breast Cancer Res Treat. 1995; 36(2):227-36.
PMID: 8534870
DOI: 10.1007/BF00666043.
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Teicher B, Holden S, Khandakar V, Herman T
J Cancer Res Clin Oncol. 1993; 119(11):645-51.
PMID: 8394365
DOI: 10.1007/BF01215982.
Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.
Chaplin D, Horsman M, Siemann D
Br J Cancer. 1993; 68(2):269-73.
PMID: 8347481
PMC: 1968547.
DOI: 10.1038/bjc.1993.326.
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Schwartz G, Teicher B, Eder Jr J, Korbut T, Holden S, Ara G
Cancer Chemother Pharmacol. 1993; 32(6):455-62.
PMID: 8258194
DOI: 10.1007/BF00685890.
In vivo modulation of several anticancer agents by beta-carotene.
Teicher B, Schwartz J, Holden S, Ara G, Northey D
Cancer Chemother Pharmacol. 1994; 34(3):235-41.
PMID: 8004757
DOI: 10.1007/BF00685083.
Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
Yoshida M, Khokhar A, Zhang Y, Thai G, Siddik Z
Cancer Chemother Pharmacol. 1994; 35(1):38-44.
PMID: 7987975
DOI: 10.1007/BF00686282.
Hypoxia and drug resistance.
Teicher B
Cancer Metastasis Rev. 1994; 13(2):139-68.
PMID: 7923547
DOI: 10.1007/BF00689633.
A preclinical model for sequential high-dose chemotherapy.
Holden S, Teicher B, Ayash L, Frei 3rd E
Cancer Chemother Pharmacol. 1995; 36(1):61-4.
PMID: 7720177
DOI: 10.1007/BF00685733.
Effects of intravenously infused Fluosol-DA 20% in rats.
West L, McIntosh N, Gendler S, Seymour C, Wisdom C
Int J Radiat Oncol Biol Phys. 1986; 12(8):1319-23.
PMID: 3759552
PMC: 7131096.
DOI: 10.1016/0360-3016(86)90163-x.
Tumor hypoxia: its impact on cancer therapy.
Moulder J, Rockwell S
Cancer Metastasis Rev. 1987; 5(4):313-41.
PMID: 3552280
DOI: 10.1007/BF00055376.
The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.
Teicher B, Herman T, Holden S, Cathcart K
Cancer Chemother Pharmacol. 1988; 21(4):286-91.
PMID: 3131033
DOI: 10.1007/BF00264193.
Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
Teicher B, Bernal S, Holden S, Cathcart K
Cancer Chemother Pharmacol. 1988; 21(4):281-5.
PMID: 3131032
DOI: 10.1007/BF00264192.
Effect of a perfluorochemical emulsion on the development of artificial lung metastases in mice.
Rockwell S, Irvin C, Nierenburg M
Clin Exp Metastasis. 1986; 4(1):45-50.
PMID: 3084150
DOI: 10.1007/BF00053472.